MedTrace Logo

A Study To Evaluate The Safety And Efficacy Of Atorvastatin In Patients With Diabetes And High Cholesterol

NCT00645424 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 155

Last updated 2021-02-18

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of atorvastatin for the treatment of Taiwanese patients with diabetes and high cholesterol.

Conditions

  • Hyperlipidemias

Interventions

DRUG

atorvastatin

Atorvastatin calcium tablets 10 mg orally once daily in the evening for 12 weeks

DRUG

atorvastatin

Atorvastatin calcium tablets 20 mg orally once daily in the evening for 12 weeks

DRUG

atorvastatin

Atorvastatin calcium tablets 40 mg orally once daily in the evening for 12 weeks

Sponsors & Collaborators

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-12-31
Completion
2004-10-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00645424 on ClinicalTrials.gov